Clinical trials - Cancer Research SA

Filter By

MTAP AMG193 20230153

Open and recruiting

Lung cancer: MTAP deleted with AMG193

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Read more: Lung cancer: MTAP deleted with AMG193
Spago 177Lu-SN201 Tumorad

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Theranostics: Advanced solid tumours with Lutetium Tumorad

A Phase I/IIa, dose escalation and dose expansion, first-in-human, open-label, multicenter, single-arm study evaluating the safety, tolerability, dosimetry, and early efficacy of [177Lu]Lu- SN201 in participants with progressive or treatment-refractory locally advanced unresectable, metastatic or recurrent solid tumors – SPAGO TumoRAD
Read more: Theranostics: Advanced solid tumours with Lutetium Tumorad
GS-US-600-6165 / EVOKE-SCLC-04

Phase 3

Open and recruiting

Small cell lung cancer: Second line Sacituzumab versus SoC

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer – GS-US-600-6165 / EVOKE-SCLC-04
Read more: Small cell lung cancer: Second line Sacituzumab versus SoC
INCA036873

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumours – INCA036873 –

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Read more: Advanced Solid Tumours – INCA036873 –
PIONERA: CO44657

Phase 3

Open and recruiting

Breast Cancer: Advanced first line ER positive – after prior adjuvant endocrine therapy – PIONERA

PIONERA: A Phase III, randomized, open-label study evaluating efficacy and safety of Giredestrant compared with Fulvestrant, both combined with a CDK4/6 inhibitor, in patients with Estrogen receptor-positive, Her2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy
Read more: Breast Cancer: Advanced first line ER positive – after prior adjuvant endocrine therapy – PIONERA
LOXO-FRA-24001 (J5E-OX-JZXA)

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced solid tumours – LY4170156 (ADC) – Folate Receptor α-Expressing cells

LOXO-FRA-24001 (J5E-OX-JZXA) – A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability andEfficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors
Read more: Advanced solid tumours – LY4170156 (ADC) – Folate Receptor α-Expressing cells
STML-ELA-0422 ELEGANT

Phase 3

Open and recruiting

Breast Cancer (high risk): ER+ Her2- on Adjuvant Endocrine Therapy – ELEGANT

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicentre, Randomized, Open-label Phase 3 Study – STML-ELA-0422 (ELEGANT)
Read more: Breast Cancer (high risk): ER+ Her2- on Adjuvant Endocrine Therapy – ELEGANT
AMT-253-01

Phase 1

Open and recruiting

Advanced Solid Tumors – AMT-253 – Anti-MUC18 ADC

First-in-Human, Phase 1 Study of AMT-253, an Anti-MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Read more: Advanced Solid Tumors – AMT-253 – Anti-MUC18 ADC
ZN-C3-005

Phase 2

Open and recruiting

Ovarian Cancer – ZN‑C3 – Platinum refractory Cancer

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Read more: Ovarian Cancer – ZN‑C3 – Platinum refractory Cancer